Tália Santana Machado de Assis1,2, Ana Rabello2, Gláucia Cota2, Guilherme Loureiro Werneck3, André Luís Ferreira de Azeredo-da-Silva4,5. 1. Centro Federal de Educação Tecnológica de Minas Gerais, Contagem, MG, Brasil. 2. Grupo de Pesquisa: Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias, Belo Horizonte, MG, Brasil. 3. Departamento de Epidemiologia, Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, RJ, Brasil. 4. Instituto de Avaliação de Tecnologia em Saúde, Porto Alegre, RS, Brasil. 5. Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil.
Abstract
INTRODUCTION: Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil. METHODS: A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies. RESULTS: IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year. CONCLUSIONS: These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.
INTRODUCTION:Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil. METHODS: A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies. RESULTS: IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year. CONCLUSIONS: These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.
Authors: Priscilla Elias Ferreira da Silva; Gerson Dos Santos Fonseca Junior; Roberta Bianchi Ambrozio; Monique Gomes Salles Tiburcio Costa; Gabrielly Borges Machado; Silvio Fernando Guimarães de Carvalho; Edward José de Oliveira; David Calhau Jorge; Luciana de Almeida Silva Teixeira Journal: Am J Trop Med Hyg Date: 2020-06-25 Impact factor: 2.345